MedTrace Logo

Progression Suppression and Retinal Regression in VEGF-resistant AMD

NCT07005323 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-06-05

No results posted yet for this study

Summary

The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy.

The main measures it aims to answer are:

* Investigation of adverse events
* Changes in clinical testing data
* Changes in vital signs
* Changes in intraocular pressure of the therapeutic eye
* Changes in testing of anterior segment of the therapeutic eye Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy.

Researchers will compare pre and post implantation of therapeutic eye to see if any safety issues recognized

Conditions

  • Neovascular Age-related Macular Degeneration (AMD)

Interventions

PROCEDURE

Pars plana vitrectomy

One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.

Sponsors & Collaborators

  • PharmaBio Corporation

    lead INDUSTRY

Principal Investigators

  • Hitoshi Kusano, M.D. · PhamaBio Coorporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-12
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07005323 on ClinicalTrials.gov